Skip to main content
Top
Published in: Journal of Gastroenterology 1/2018

01-01-2018 | Original Article—Liver, Pancreas, and Biliary Tract

Nationwide survey of hereditary pancreatitis in Japan

Authors: Atsushi Masamune, Kazuhiro Kikuta, Shin Hamada, Eriko Nakano, Kiyoshi Kume, Ayano Inui, Toshiaki Shimizu, Yoshifumi Takeyama, Masaki Nio, Tooru Shimosegawa

Published in: Journal of Gastroenterology | Issue 1/2018

Login to get access

Abstract

Background

Hereditary pancreatitis (HP) is a rare cause of chronic pancreatitis. We here report a nationwide survey to clarify the epidemiological, genetic, and clinical features of HP in Japan.

Methods

Target subjects were patients with HP and their family members who had visited selected hospitals between 2005 and 2014. This study consisted of two-stage surveys; patients with HP were identified by the first questionnaire and their clinical features were assessed by the second questionnaire.

Results

Two hundred seventy-one patients (153 males and 118 females) in 100 families diagnosed based on the Japanese criteria or 231 patients (131 males and 100 females) patients in 80 families based on the EUROPAC criteria were reported. Of the families undertaking genetic tests, 41% had the PRSS1 mutations (p.R122H 33%, p.N29I 8%) and 36% had the SPINK1 mutations (p.N34S 22%, c.194+2T>C 14%, p.P45S 1%). The mean age at symptom onset was 17.8 years. The cumulative rates of pancreatic exocrine insufficiency and diabetes mellitus were 16.1 and 5.5% at 20 years old, and 45.3 and 28.2% at 40 years, respectively. Forty-four percent of the patients underwent endoscopic treatment and/or surgery. The cumulative rate of pancreatic cancer diagnosis was 2.8% at 40 years old, 10.8% at 60 years, and 22.8% at 70 years.

Conclusions

HP was characterized by early disease onset, frequent development of pancreatic exocrine insufficiency and diabetes mellitus, requirement of endoscopic treatment and/or surgery, and increased risk of pancreatic cancer. PRSS1 and SPINK1 mutations serve as genetic background for HP in Japan.
Literature
1.
go back to reference Rebours V, Lévy P, Ruszniewski P. An overview of hereditary pancreatitis. Dig Liver Dis. 2012;44:8–15.CrossRefPubMed Rebours V, Lévy P, Ruszniewski P. An overview of hereditary pancreatitis. Dig Liver Dis. 2012;44:8–15.CrossRefPubMed
3.
go back to reference Comfort MW, Steinberg AG. Pedigree of a family with hereditary chronic relapsing pancreatitis. Gastroenterology. 1952;21:54–63.PubMed Comfort MW, Steinberg AG. Pedigree of a family with hereditary chronic relapsing pancreatitis. Gastroenterology. 1952;21:54–63.PubMed
4.
go back to reference Whitcomb DC, Gorry MC, Preston RA, et al. Hereditary pancreatitis is caused by a mutation in the cationic trypsinogen gene. Nat Genet. 1996;14:141–5.CrossRefPubMed Whitcomb DC, Gorry MC, Preston RA, et al. Hereditary pancreatitis is caused by a mutation in the cationic trypsinogen gene. Nat Genet. 1996;14:141–5.CrossRefPubMed
5.
go back to reference Gorry MC, Gabbaizedeh D, Furey W, et al. Mutations in the cationic trypsinogen gene are associated with recurrent acute and chronic pancreatitis. Gastroenterology. 1997;113:1063–8.CrossRefPubMed Gorry MC, Gabbaizedeh D, Furey W, et al. Mutations in the cationic trypsinogen gene are associated with recurrent acute and chronic pancreatitis. Gastroenterology. 1997;113:1063–8.CrossRefPubMed
6.
go back to reference Howes N, Lerch MM, Greenhalf W, et al. Clinical and genetic characteristics of hereditary pancreatitis in Europe. Clin Gastroenterol Hepatol. 2004;2:252–61.CrossRefPubMed Howes N, Lerch MM, Greenhalf W, et al. Clinical and genetic characteristics of hereditary pancreatitis in Europe. Clin Gastroenterol Hepatol. 2004;2:252–61.CrossRefPubMed
7.
go back to reference Rebours V, Boutron-Ruault MC, Schnee M, et al. The natural history of hereditary pancreatitis: a national series. Gut. 2009;58:97–103.CrossRefPubMed Rebours V, Boutron-Ruault MC, Schnee M, et al. The natural history of hereditary pancreatitis: a national series. Gut. 2009;58:97–103.CrossRefPubMed
8.
go back to reference Joergensen MT, Brusgaard K, Crüger DG, et al. Genetic, epidemiological, and clinical aspects of hereditary pancreatitis: a population-based cohort study in Denmark. Am J Gastroenterol. 2010;105:1876–83.CrossRefPubMed Joergensen MT, Brusgaard K, Crüger DG, et al. Genetic, epidemiological, and clinical aspects of hereditary pancreatitis: a population-based cohort study in Denmark. Am J Gastroenterol. 2010;105:1876–83.CrossRefPubMed
9.
go back to reference Witt H, Luck W, Hennies HC, et al. Mutations in the gene encoding the serine protease inhibitor, Kazal type 1 are associated with chronic pancreatitis. Nat Genet. 2000;25:213–6.CrossRefPubMed Witt H, Luck W, Hennies HC, et al. Mutations in the gene encoding the serine protease inhibitor, Kazal type 1 are associated with chronic pancreatitis. Nat Genet. 2000;25:213–6.CrossRefPubMed
10.
go back to reference Kume K, Masamune A, Kikuta K, et al. [–215G>A; IVS3+2T>C] mutation in the SPINK1 gene causes exon 3 skipping and loss of the trypsin binding site. Gut. 2006;55:1214.CrossRefPubMedPubMedCentral Kume K, Masamune A, Kikuta K, et al. [–215G>A; IVS3+2T>C] mutation in the SPINK1 gene causes exon 3 skipping and loss of the trypsin binding site. Gut. 2006;55:1214.CrossRefPubMedPubMedCentral
11.
go back to reference Zou WB, Boulling A, Masamune A, et al. No association between CEL-HYB hybrid allele and chronic pancreatitis in Asian populations. Gastroenterology. 2016;150:1558–1560.e5.CrossRefPubMedPubMedCentral Zou WB, Boulling A, Masamune A, et al. No association between CEL-HYB hybrid allele and chronic pancreatitis in Asian populations. Gastroenterology. 2016;150:1558–1560.e5.CrossRefPubMedPubMedCentral
12.
13.
go back to reference Otsuki M, Nishimori I, Hayakawa T, et al. Hereditary pancreatitis: clinical characteristics and diagnostic criteria in Japan. Pancreas. 2004;28:200–6.CrossRefPubMed Otsuki M, Nishimori I, Hayakawa T, et al. Hereditary pancreatitis: clinical characteristics and diagnostic criteria in Japan. Pancreas. 2004;28:200–6.CrossRefPubMed
14.
go back to reference American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2014;37(Suppl 1):S81–90.CrossRef American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2014;37(Suppl 1):S81–90.CrossRef
15.
go back to reference Nishimori I, Kamakura M, Fujikawa-Adachi K, et al. Mutations in exons 2 and 3 of the cationic trypsinogen gene in Japanese families with hereditary pancreatitis. Gut. 1999;44:259–63.CrossRefPubMedPubMedCentral Nishimori I, Kamakura M, Fujikawa-Adachi K, et al. Mutations in exons 2 and 3 of the cationic trypsinogen gene in Japanese families with hereditary pancreatitis. Gut. 1999;44:259–63.CrossRefPubMedPubMedCentral
16.
go back to reference Kume K, Masamune A, Mizutamari H, et al. Mutations in the serine protease inhibitor Kazal Type 1 (SPINK1) gene in Japanese patients with pancreatitis. Pancreatology. 2005;5:354–60.CrossRefPubMed Kume K, Masamune A, Mizutamari H, et al. Mutations in the serine protease inhibitor Kazal Type 1 (SPINK1) gene in Japanese patients with pancreatitis. Pancreatology. 2005;5:354–60.CrossRefPubMed
17.
go back to reference Nakano E, Masamune A, Niihori T, et al. Targeted next-generation sequencing effectively analyzed the cystic fibrosis transmembrane conductance regulator gene in pancreatitis. Dig Dis Sci. 2015;60:1297–307.CrossRefPubMed Nakano E, Masamune A, Niihori T, et al. Targeted next-generation sequencing effectively analyzed the cystic fibrosis transmembrane conductance regulator gene in pancreatitis. Dig Dis Sci. 2015;60:1297–307.CrossRefPubMed
18.
go back to reference Rosendahl J, Witt H, Szmola R, et al. Chymotrypsin C (CTRC) variants that diminish activity or secretion are associated with chronic pancreatitis. Nat Genet. 2008;40:78–82.CrossRefPubMed Rosendahl J, Witt H, Szmola R, et al. Chymotrypsin C (CTRC) variants that diminish activity or secretion are associated with chronic pancreatitis. Nat Genet. 2008;40:78–82.CrossRefPubMed
19.
20.
go back to reference Kume K, Masamune A, Ariga H, et al. Do genetic variants in the SPINK1 gene affect the level of serum PSTI? J Gastroenterol. 2012;47:1267–74.CrossRefPubMed Kume K, Masamune A, Ariga H, et al. Do genetic variants in the SPINK1 gene affect the level of serum PSTI? J Gastroenterol. 2012;47:1267–74.CrossRefPubMed
21.
go back to reference Hirota M, Shimosegawa T, Masamune A, et al. The seventh nationwide epidemiological survey for chronic pancreatitis in Japan: clinical significance of smoking habit in Japanese patients. Pancreatology. 2014;14:490–6.CrossRefPubMed Hirota M, Shimosegawa T, Masamune A, et al. The seventh nationwide epidemiological survey for chronic pancreatitis in Japan: clinical significance of smoking habit in Japanese patients. Pancreatology. 2014;14:490–6.CrossRefPubMed
22.
go back to reference Oracz G, Kolodziejczyk E, Sobczynska-Tomaszewska A, et al. The clinical course of hereditary pancreatitis in children—A comprehensive analysis of 41 cases. Pancreatology. 2016;16:535–41.CrossRefPubMed Oracz G, Kolodziejczyk E, Sobczynska-Tomaszewska A, et al. The clinical course of hereditary pancreatitis in children—A comprehensive analysis of 41 cases. Pancreatology. 2016;16:535–41.CrossRefPubMed
23.
go back to reference Issa Y, Bruno MJ, Bakker OJ, et al. Treatment options for chronic pancreatitis. Nat Rev Gastroenterol Hepatol. 2014;11:556–64.CrossRefPubMed Issa Y, Bruno MJ, Bakker OJ, et al. Treatment options for chronic pancreatitis. Nat Rev Gastroenterol Hepatol. 2014;11:556–64.CrossRefPubMed
25.
go back to reference Kargl S, Kienbauer M, Duba HC, et al. Therapeutic step-up strategy for management of hereditary pancreatitis in children. J Pediatr Surg. 2015;50:511–4.CrossRefPubMed Kargl S, Kienbauer M, Duba HC, et al. Therapeutic step-up strategy for management of hereditary pancreatitis in children. J Pediatr Surg. 2015;50:511–4.CrossRefPubMed
27.
go back to reference Lowenfels AB, Maisonneuve P, DiMagno EP, et al. Hereditary pancreatitis and the risk of pancreatic cancer. International Hereditary Pancreatitis Study Group. J Natl Cancer Inst. 1997;89:442–6.CrossRefPubMed Lowenfels AB, Maisonneuve P, DiMagno EP, et al. Hereditary pancreatitis and the risk of pancreatic cancer. International Hereditary Pancreatitis Study Group. J Natl Cancer Inst. 1997;89:442–6.CrossRefPubMed
28.
go back to reference Rebours V, Boutron-Ruault MC, Schnee M, et al. Risk of pancreatic adenocarcinoma in patients with hereditary pancreatitis: a national exhaustive series. Am J Gastroenterol. 2008;103:111–9.CrossRefPubMed Rebours V, Boutron-Ruault MC, Schnee M, et al. Risk of pancreatic adenocarcinoma in patients with hereditary pancreatitis: a national exhaustive series. Am J Gastroenterol. 2008;103:111–9.CrossRefPubMed
29.
go back to reference Masamune A, Mizutamari H, Kume K, et al. Hereditary pancreatitis as the premalignant disease: a Japanese case of pancreatic cancer involving the SPINK1 gene mutation N34S. Pancreas. 2004;28:305–10.CrossRefPubMed Masamune A, Mizutamari H, Kume K, et al. Hereditary pancreatitis as the premalignant disease: a Japanese case of pancreatic cancer involving the SPINK1 gene mutation N34S. Pancreas. 2004;28:305–10.CrossRefPubMed
30.
Metadata
Title
Nationwide survey of hereditary pancreatitis in Japan
Authors
Atsushi Masamune
Kazuhiro Kikuta
Shin Hamada
Eriko Nakano
Kiyoshi Kume
Ayano Inui
Toshiaki Shimizu
Yoshifumi Takeyama
Masaki Nio
Tooru Shimosegawa
Publication date
01-01-2018
Publisher
Springer Japan
Published in
Journal of Gastroenterology / Issue 1/2018
Print ISSN: 0944-1174
Electronic ISSN: 1435-5922
DOI
https://doi.org/10.1007/s00535-017-1388-0

Other articles of this Issue 1/2018

Journal of Gastroenterology 1/2018 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine